The United Kingdom and the United States have hammered out a significant trade agreement that will maintain no duties on UK medicine exports going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost spending on drugs through the NHS. This move guarantees that import taxes on these vital goods will remain at nothing for a timeframe of the next three years.
This agreement comes after recent statements to significantly raise duties on branded pharmaceutical imports, with potential rates discussed as high as one hundred percent.
"This agreement with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. drug exports," a statement noted.
Trade Importance
Medicines represent one of the Britain's most significant goods shipped to the United States, which is by far the biggest destination for leading companies like GSK and AstraZeneca.
Statistics reveal that in the year prior to September, the UK shipped drugs totaling £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that span.
"This agreement safeguards work, boosts capital expenditure and sets the stage for the UK to establish itself as a worldwide center for medical research," a minister commented.
Key UK Commitments
The agreement involves several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a goal to increase overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must return to the NHS to control costs will be capped at 15%. Previously, refunds were more than 20%.
Broader Context
This agreement takes place against a ongoing row between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
These tensions were heightened by arguments that US patients were paying several times more for the equivalent treatments than patients in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had declined as a percentage of its total funding over the previous ten-year period.
